Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies

Virology

Volumn 362, Issue 1, 2007, Pages 26-37

  Kuate, Seraphin ^a   Cinatl, Jindrich ^b   Doerr, Hans Wilhelm ^b   Überla, Klaus ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Adenoviral vector; Exosome; S spike; SARS CoV; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CELL SURFACE PROTEIN; EXOSOMAL VACCINE; NEUTRALIZING ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; VITRONECTIN;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, SECONDARY; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NEOPLASMS; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; SARS VIRUS; TRANSPORT VESICLES; VACCINES, SYNTHETIC; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

MUS; SARS CORONAVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 34247243255     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.12.011     Document Type: Article

References (61)

1. Admyre C., Grunewald J., Thyberg J., Gripenback S., Tornling G., Eklund A., Scheynius A., and Gabrielsson S. Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. Eur. Respir. J. 22 (2003) 578-583
2. Amigorena S. Cancer immunotherapy using dendritic cell-derived exosomes. Medicina (B Aires) 60 Suppl. 2 (2000) 51-54
3. Andersson A.M., Melin L., Bean A., and Pettersson R.F. A retention signal necessary and sufficient for Golgi localization maps to the cytoplasmic tail of a Bunyaviridae (Uukuniemi virus) membrane glycoprotein. J. Virol. 71 (1997) 4717-4727
4. Andre F., Andersen M., Wolfers J., Lozier A., Raposo G., Serra V., Ruegg C., Flament C., Angevin E., Amigorena S., and Zitvogel L. Exosomes in cancer immunotherapy: preclinical data. Adv. Exp. Med. Biol. 495 (2001) 349-354
5. Andre F., Schartz N.E., Chaput N., Flament C., Raposo G., Amigorena S., Angevin E., and Zitvogel L. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 20 Suppl. 4 (2002) A28-A31
6. Andre F., Chaput N., Schartz N.E., Flament C., Aubert N., Bernard J., Lemonnier F., Raposo G., Escudier B., Hsu D.H., Tursz T., Amigorena S., Angevin E., and Zitvogel L. Exosomes as potent cell-free peptide-based vaccine: I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 172 (2004) 2126-2136
7. Bangari D.S., and Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24 (2006) 849-862
8. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J.C., Korioth-Schmitz B., Newberg M.H., Gorgone D.A., Lifton M.A., Panicali D.L., Nabel G.J., Letvin N.L., and Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172 (2004) 6290-6297
9. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., Brimnes M.K., Moltedo B., Moran T.M., and Steinman R.M. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199 (2004) 815-824
10. Brown D.A., Crise B., and Rose J.K. Mechanism of membrane anchoring affects polarized expression of two proteins in MDCK cells. Science 245 (1989) 1499-1501
11. Chan-Yeung M. Severe acute respiratory syndrome (SARS) and healthcare workers. Int. J. Occup. Environ. Health 10 (2004) 421-427
12. Chan-Yeung M., and Yu W.C. Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report. BMJ 326 (2003) 850-852
13. Chan-Yeung M., Seto W.H., and Sung J.J. Severe acute respiratory syndrome: patients were epidemiologically linked. BMJ 326 (2003) 1393
14. Chapple S.D.J., and Jones I.M. Non-polar distribution of green fluorescent protein on the surface of Autographa californica nucleopolyhedrovirus using a heterologous membrane anchor. J. Biotechnol. 95 (2002) 269-275
15. Chaput N., Schartz N.E., Andre F., and Zitvogel L. Exosomes for immunotherapy of cancer. Adv. Exp. Med. Biol. 532 (2003) 215-221
16. Chaput N., Taieb J., Schartz N., Flament C., Novault S., Andre F., and Zitvogel L. The potential of exosomes in immunotherapy of cancer. Blood Cells, Mol. Dis. 35 (2005) 111-115
17. Chen W., Wang J., Shao C., Liu S., Yu Y., Wang Q., and Cao X. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur. J. Immunol. 36 (2006) 1598-1607
18. Clayton A., Turkes A., Navabi H., Mason D.M., and Tabi Z. Induction of heat shock proteins in B cell exosomes. J. Cell Sci. 118 (2005) 3631-3638
19. Compton T., Ivanov I.E., Gottlieb T., Rindler M., Adesnik M., and Sabatini D.D. A sorting signal for the basolateral delivery of the vesicular stomatitis virus (VSV) G protein lies in its luminal domain: analysis of the targeting of VSV G-influenza hemagglutinin chimeras. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 4112-4116
20. Delcayre A., Shu H., and Le Pecq J.B. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway. Expert Rev. Anticancer Ther. 5 (2005) 537-547
21. Denzer K., van E.M., Kleijmeer M.J., Jakobson E., de G.C., and Geuze H.J. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J. Immunol. 165 (2000) 1259-1265
22. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A.M., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D.M.E., Schmitz H., and Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1976
23. Drosten C., Preiser W., Gunther S., Schmitz H., and Doerr H.W. Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol. Med. 9 (2003) 325-327
24. DuBridge R.B., Tang P., Hsia H.C., Leong P.M., Miller J.H., and Calos M.P. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7 (1987) 379-387
25. Fouchier R.A.M., Meyer B.E., Simon J.H.M., Fischer U., and Malim M.H. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J. 16 (1997) 4531-4539
26. Giroglou T., Cinatl J., Rabenau H., Drosten C., Schwalbe H., Doerr H.W., and von Laer D. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J. Virol. 78 (2004) 9007-9015
27. Hart K.C., Xu Y.F., Meyer A.N., Lee B.A., and Donoghue D.J. The V-sis oncoprotein loses transforming activity when targeted to the early Golgi-complex. J. Cell Biol. 127 (1994) 1843-1857
28. He T.C., Zhou S.B., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 2509-2514
29. Hemler M.E. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu. Rev. Cell Dev. Biol. 19 (2003) 397-422
30. Ho A.S., Sung J.J., and Chan-Yeung M. An outbreak of severe acute respiratory syndrome among hospital workers in a community hospital in Hong Kong. Ann. Intern. Med. 139 (2003) 564-567
31. Hofmann H., and Pohlmann S. Cellular entry of the SARS coronavirus. Trends Microbiol. 12 (2004) 466-472
32. Hofmann H., Hattermann K., Marzi A., Gramberg T., Geier M., Krumbiegel M., Kuate S., Uberla K., Niedrig M., and Pohlmann S. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol. 78 (2004) 6134-6142
33. Jeffers S.A., Tusell S.M., Gillim-Ross L., Hemmila E.M., Achenbach J.E., Babcock G.J., Thomas W.D., Thackray L.B., Young M.D., Mason R.J., Ambrosino D.M., Wentworth D.E., DeMartini J.C., and Holmes K.V. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 15748-15753
34. Jin Y., and Wright S.E. The transmembrane domain of vesicular stomatitis virus glycoprotein suffices to anchor HIV-1 envelope gp120 expressed by a recombinant vaccinia virus. Int. J. Mol. Med. 12 (2003) 11-16
35. Keng C.T., Zhang A., Shen S., Lip K.M., Fielding B.C., Tan T.H.P., Chou C.F., Loh C.B., Wang S., Fu J., Yang X., Lim S.G., Hong W., and Tan Y.J. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J. Virol. 79 (2005) 3289-3296
36. Kuate S., Stefanou D., Hoffmann D., Wildner O., and Uberla K. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses. J. Gene Med. 6 (2004) 1197-1205
37. Kuate S., Stahl-Hennig C., Stoiber H., Nchinda G., Floto A., Franz M., Sauermann U., Bredl S., Deml L., Ignatius R., Norley S., Racz P., Tenner-Racz K., Steinman R.M., Wagner R., and Uberla K. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. Virology 351 1 (2006) 133-144
38. Li W.H., Moore M.J., Vasilieva N., Sui J.H., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
39. Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffin O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.E., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., and Roper R.L. The genome sequence of the SARS-associated coronavirus. Science 300 (2003) 1399-1404
40. Marsac D., Loirat D., Petit C., Schwartz O., and Michel M.L. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J. Virol. 76 (2002) 7544-7553
41. McQueen N., Nayak D.P., Stephens E.B., and Compans R.W. Polarized expression of a chimeric protein in which the transmembrane and cytoplasmic domains of the influenza virus hemagglutinin have been replaced by those of the vesicular stomatitis virus G protein. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 9318-9322
42. Mears R., Craven R.A., Hanrahan S., Totty N., Upton C., Young S.L., Patel P., Selby P.J., and Banks R.E. Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics 4 (2004) 4019-4031
43. Mittereder N., March K.L., and Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70 (1996) 7498-7509
44. Miyoshi H., Blomer U., Takahashi M., Gage F.H., and Verma I.M. Development of a self-inactivating lentivirus vector. J. Virol. 72 (1998) 8150-8157
45. Owens R.J., and Rose J.K. Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus. J. Virol. 67 (1993) 360-365
46. Peche H., Heslan M., Usal C., Amigorena S., and Cuturi M.C. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation 76 (2003) 1503-1510
47. Peiris J.S., Guan Y., and Yuen K.Y. Severe acute respiratory syndrome. Nat. Med. 10 (2004) S88-S97
48. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S.X., Tamin A., Lowe L., Frace M., Derisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J., and Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
49. Sandrin V., Muriaux D., Darlix J.L., and Cosset F.L. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J. Virol. 78 (2004) 7153-7164
50. Schartz N.E., Chaput N., Andre F., and Zitvogel L. From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. Curr. Opin. Mol. Ther. 4 (2002) 372-381
51. Schnell T., Foley P., Wirth M., Munch J., and Uberla K. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum. Gene Ther. 11 (2000) 439-447
52. Southgate C., Zapp M.L., and Green M.R. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein. Nature 345 (1990) 640-642
53. Spiga O., Bernini A., Ciutti A., Chiellini S., Menciassi N., Finetti F., Causarono V., Anselmi F., Prischi F., and Niccolai N. Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem. Biophys. Res. Commun. 310 (2003) 78-83
54. Taieb J., Chaput N., and Zitvogel L. Dendritic cell-derived exosomes as cell-free peptide-based vaccines. Crit. Rev. Immunol. 25 (2005) 215-223
55. Wagner R., Graf M., Bieler K., Wolf H., Grunwald T., Foley P., and Uberla K. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum. Gene Ther. 11 (2000) 2403-2413
56. Wang Y.D., Li Y., Xu G.B., Dong X.Y., Yang X.A., Feng Z.R., Tian C., and Chen W.F. Detection of antibodies against SARS-CoV in serum from SARS-infected donors with ELISA and Western blot. Clin. Immunol. 113 (2004) 145-150
57. Wubbolts R., Leckie R.S., Veenhuizen P.T.M., Schwarzmann G., Möbius W., Hoernschemeyer J., Slot J.W., Geuze H.J., and Stoorvogel W. Proteomic and biochemical analyses of human B cell-derived exosomes: potential implications for their function and multivesicular body formation. J. Biol. Chem. 278 (2003) 10963-10972
58. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77 (2003) 799-803
59. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., and Nabel G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 (2004) 561-564
60. Zeng F.Y., Chow K.Y.C., Hon C.C., Law K.M., Yip C.W., Chan K.H., Peiris J.S.M., and Leung F.C.C. Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem. Biophys. Res. Commun. 315 (2004) 1134-1139
61. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G., and Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4 (1998) 594-600